{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:54:08Z","timestamp":1790970848526,"version":"4.1.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s11864-024-01210-7","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T22:01:43Z","timestamp":1718143303000},"page":"897-913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies"],"prefix":"10.1007","volume":"25","author":[{"given":"Despoina","family":"Pantazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Alivertis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros D.","family":"Tselepis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"issue":"3","key":"1210_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.21037\/jtd.2017.02.75","volume":"9","author":"H Nagai","year":"2017","unstructured":"Nagai H, Kim YH. Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis. 2017;9(3):448\u201351.","journal-title":"J Thorac Dis"},{"issue":"3","key":"1210_CR2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/cncr.27772","volume":"119","author":"AA Khorana","year":"2013","unstructured":"Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648\u201355.","journal-title":"Cancer"},{"key":"1210_CR3","doi-asserted-by":"publisher","first-page":"394740","DOI":"10.4061\/2011\/394740","volume":"2011","author":"AD Blann","year":"2011","unstructured":"Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011;2011:394740.","journal-title":"Cardiol Res Pract"},{"issue":"4","key":"1210_CR4","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1055\/s-0040-1708481","volume":"120","author":"A Abdulla","year":"2020","unstructured":"Abdulla A, Davis WM, Ratnaweera N, Szefer E, Ballantyne Scott B, Lee AYY. A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer. Thromb Haemost. 2020;120(4):702\u201313.","journal-title":"Thromb Haemost"},{"issue":"1","key":"1210_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.amjmed.2005.06.058","volume":"119","author":"PD Stein","year":"2006","unstructured":"Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119(1):60\u20138.","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"1210_CR6","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.thromres.2018.01.028","volume":"164","author":"GH Lyman","year":"2018","unstructured":"Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018;164(Suppl 1):S112\u20138.","journal-title":"Thromb Res"},{"issue":"3","key":"1210_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632\u20134.","journal-title":"J Thromb Haemost"},{"key":"1210_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4137\/CMO.S18991","volume":"8","author":"G Elyamany","year":"2014","unstructured":"Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014;8:129\u201337.","journal-title":"Clin Med Insights Oncol"},{"issue":"14","key":"1210_CR9","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959\u201369.","journal-title":"Blood"},{"key":"1210_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/archinte.162.11.1245","volume":"162","author":"JAOFW Heit","year":"2002","unstructured":"Heit JAOFW, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ 3rd. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch Intern Med. 2002;162:1245\u20138.","journal-title":"Arch Intern Med"},{"issue":"6","key":"1210_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715\u201322.","journal-title":"JAMA"},{"issue":"10","key":"1210_CR12","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484\u20138.","journal-title":"Blood"},{"issue":"2","key":"1210_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11239-020-02180-x","volume":"50","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Haas S, Ageno W, Goldhaber SZ, Turpie AGG, Goto S, et al. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. J Thromb Thrombolysis. 2020;50(2):267\u201377.","journal-title":"J Thromb Thrombolysis"},{"issue":"8","key":"1210_CR14","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","volume":"70","author":"BB Navi","year":"2017","unstructured":"Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, et al. Risk of Arterial Thromboembolism in Patients With Cancer. J Am Coll Cardiol. 2017;70(8):926\u201338.","journal-title":"J Am Coll Cardiol"},{"key":"1210_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.thromres.2019.10.004","volume":"184","author":"J Yu","year":"2019","unstructured":"Yu J, Li A, Laureano M, Crowther M. Frequency of arterial thromboembolism in populations with malignancies: A systematic review. Thromb Res. 2019;184:16\u201323.","journal-title":"Thromb Res"},{"issue":"6","key":"1210_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1182\/blood-2006-10-053736","volume":"110","author":"A Varki","year":"2007","unstructured":"Varki A. Trousseau\u2019s syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110(6):1723\u20139.","journal-title":"Blood"},{"key":"1210_CR17","unstructured":"R. V. Weitere Unter-suchungen huber die Verstopgung der Lungenarterie und ihre Folgen. In: Virchow R, ed. Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Meidinger Sohn: Frankfurt am Main. 1856;227\u2013380."},{"issue":"6","key":"1210_CR18","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.thromres.2015.10.043","volume":"136","author":"J Portillo","year":"2015","unstructured":"Portillo J, de la Rocha IV, Font L, Braester A, Madridano O, Peromingo JA, et al. Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry. Thromb Res. 2015;136(6):1199\u2013203.","journal-title":"Thromb Res"},{"issue":"3","key":"1210_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/1358863X20914978","volume":"25","author":"U Campia","year":"2020","unstructured":"Campia U. Vascular effects of cancer treatments. Vasc Med (London, England). 2020;25(3):226\u201334.","journal-title":"Vasc Med (London, England)"},{"key":"1210_CR20","first-page":"9","volume":"1","author":"A Falanga","year":"2005","unstructured":"Falanga A, Rickles FR. The pathogenesis of thrombosis in cancer. New Oncol Thrombosis. 2005;1:9\u201316.","journal-title":"New Oncol Thrombosis"},{"issue":"2","key":"1210_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jjcc.2018.02.011","volume":"72","author":"M Mukai","year":"2018","unstructured":"Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018;72(2):89\u201393.","journal-title":"J Cardiol"},{"issue":"6","key":"1210_CR22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jtha.2023.02.029","volume":"21","author":"A Falanga","year":"2023","unstructured":"Falanga A, Marchetti M. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. J Thromb Haemost. 2023;21(6):1397\u2013408.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"1210_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7326\/0003-4819-119-8-199310150-00008","volume":"119","author":"RL Nachman","year":"1993","unstructured":"Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med. 1993;119(8):819\u201327.","journal-title":"Ann Intern Med"},{"key":"1210_CR24","doi-asserted-by":"publisher","unstructured":"Prosciak MP SS. Hypercoagulable states: A concise review. Int J Acad Med 2017;3:Suppl S1:82\u201395.\u00a0https:\/\/doi.org\/10.4103\/IJAM.IJAM_18_17.","DOI":"10.4103\/IJAM.IJAM_18_17"},{"issue":"7031","key":"1210_CR25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03357","volume":"434","author":"C Boccaccio","year":"2005","unstructured":"Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature. 2005;434(7031):396\u2013400.","journal-title":"Nature"},{"issue":"4","key":"1210_CR26","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1182\/blood-2004-05-2042","volume":"105","author":"JL Yu","year":"2005","unstructured":"Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105(4):1734\u201341.","journal-title":"Blood"},{"issue":"4","key":"1210_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1055\/s-0039-1687894","volume":"45","author":"Y Hisada","year":"2019","unstructured":"Hisada Y, Mackman N. Tissue factor and cancer: regulation, tumor growth, and metastasis. Semin Thromb Hemost. 2019;45(4):385\u201395.","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 1","key":"1210_CR28","first-page":"S82","volume":"87","author":"AA Khorana","year":"2012","unstructured":"Khorana AA. Cancer and coagulation. Am J Hematol. 2012;87(Suppl 1):S82\u20137.","journal-title":"Am J Hematol"},{"issue":"S2","key":"1210_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/HS9.0000000000000239","volume":"3","author":"LP-D Diane Mege","year":"2019","unstructured":"Diane Mege LP-D, Dubois C. Mechanisms of cancer-associated thrombosis. HemaSphere. 2019;3(S2):19\u201321.","journal-title":"HemaSphere"},{"issue":"12","key":"1210_CR30","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1111\/jth.13871","volume":"15","author":"K Date","year":"2017","unstructured":"Date K, Ettelaie C, Maraveyas A. Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer. J Thromb Haemost. 2017;15(12):2289\u201399.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"1210_CR31","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/jth.14481","volume":"17","author":"R Nieuwland","year":"2019","unstructured":"Nieuwland R, Gardiner C, Dignat-George F, Mullier F, Mackman N, Woodhams B, et al. Toward standardization of assays measuring extracellular vesicle-associated tissue factor activity. J Thromb Haemost. 2019;17(8):1261\u20134.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"1210_CR32","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1084\/jem.20082297","volume":"206","author":"GM Thomas","year":"2009","unstructured":"Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med. 2009;206(9):1913\u201327.","journal-title":"J Exp Med"},{"issue":"1","key":"1210_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/jth.13181","volume":"14","author":"JE Geddings","year":"2016","unstructured":"Geddings JE, Hisada Y, Boulaftali Y, Getz TM, Whelihan M, Fuentes R, et al. Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost. 2016;14(1):153\u201366.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"1210_CR34","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3892\/ijo.2017.4170","volume":"51","author":"A Rousseau","year":"2017","unstructured":"Rousseau A, Van Dreden P, Khaterchi A, Larsen AK, Elalamy I, Gerotziafas GT. Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer. Int J Oncol. 2017;51(6):1793\u2013800.","journal-title":"Int J Oncol"},{"issue":"11","key":"1210_CR35","first-page":"3062","volume":"51","author":"T Utsugi","year":"1991","unstructured":"Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991;51(11):3062\u20136.","journal-title":"Cancer Res"},{"issue":"Pt 1","key":"1210_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.semcancer.2017.08.012","volume":"52","author":"B Sharma","year":"2018","unstructured":"Sharma B, Kanwar SS. Phosphatidylserine: A cancer cell targeting biomarker. Semin Cancer Biol. 2018;52(Pt 1):17\u201325.","journal-title":"Semin Cancer Biol"},{"key":"1210_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.thromres.2020.01.025","volume":"188","author":"M Yu","year":"2020","unstructured":"Yu M, Li T, Li B, Liu Y, Wang L, Zhang J, et al. Phosphatidylserine-exposing blood cells, microparticles and neutrophil extracellular traps increase procoagulant activity in patients with pancreatic cancer. Thromb Research. 2020;188:5\u201316.","journal-title":"Thromb Research"},{"key":"1210_CR38","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1038\/ncomms7387","volume":"6","author":"VR Krishnamurthy","year":"2015","unstructured":"Krishnamurthy VR, Sardar MY, Ying Y, Song X, Haller C, Dai E, et al. Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo. Nat Commun. 2015;6:6387.","journal-title":"Nat Commun"},{"key":"1210_CR39","doi-asserted-by":"publisher","first-page":"6138145","DOI":"10.1155\/2017\/6138145","volume":"2017","author":"J Kappelmayer","year":"2017","unstructured":"Kappelmayer J, Nagy B Jr. The Interaction of Selectins and PSGL-1 as a Key Component in Thrombus Formation and Cancer Progression. BioMed Res Int. 2017;2017:6138145.","journal-title":"BioMed Res Int"},{"issue":"6","key":"1210_CR40","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1172\/JCI200318882","volume":"112","author":"M Wahrenbrock","year":"2003","unstructured":"Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112(6):853\u201362.","journal-title":"J Clin Invest"},{"issue":"5","key":"1210_CR41","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1073\/pnas.0435410100","volume":"100","author":"T Inaba","year":"2003","unstructured":"Inaba T, Sano H, Kawahito Y, Hla T, Akita K, Toda M, et al. Induction of cyclooxygenase-2 in monocyte\/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci USA. 2003;100(5):2736\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1210_CR42","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/bjc.2016.170","volume":"115","author":"AJFJ Woei","year":"2016","unstructured":"Woei AJFJ, Tesselaar ME, Garcia Rodriguez P, Romijn FP, Bertina RM, Osanto S. Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? Br J Cancer. 2016;115(3):332\u20138.","journal-title":"Br J Cancer."},{"issue":"19","key":"1210_CR43","doi-asserted-by":"publisher","first-page":"9453","DOI":"10.1158\/0008-5472.CAN-06-1803","volume":"66","author":"S Koizume","year":"2006","unstructured":"Koizume S, Jin MS, Miyagi E, Hirahara F, Nakamura Y, Piao JH, et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res. 2006;66(19):9453\u201360.","journal-title":"Cancer Res"},{"key":"1210_CR44","first-page":"1","volume-title":"Cancer-associated thrombosis: New findings in translational science, prevention, and treatment","author":"CCP Boccaccio","year":"2008","unstructured":"Boccaccio CCP. Oncogenes, cancer, and hemostasis. In: Khorana AA, Francis CW, editors. Cancer-associated thrombosis: New findings in translational science, prevention, and treatment. Informa Healthcare: New York; 2008. p. 1\u201313."},{"key":"1210_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-3-030-20315-3_2","volume":"179","author":"A Falanga","year":"2019","unstructured":"Falanga A, Schieppati F, Russo L. Pathophysiology 1. Mechanisms of thrombosis in cancer patients. Cancer Treat Res Commun. 2019;179:11\u201336.","journal-title":"Cancer Treat Res Commun."},{"issue":"2","key":"1210_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0049-3848(75)90018-3","volume":"6","author":"SG Gordon","year":"1975","unstructured":"Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res. 1975;6(2):127\u201337.","journal-title":"Thromb Res"},{"issue":"2","key":"1210_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00001721-199703000-00001","volume":"8","author":"SG Gordon","year":"1997","unstructured":"Gordon SG, Mielicki WP. Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis. 1997;8(2):73\u201386.","journal-title":"Blood Coagul Fibrinolysis."},{"issue":"11","key":"1210_CR48","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/blood-2015-01-622811","volume":"126","author":"KF Nickel","year":"2015","unstructured":"Nickel KF, Ronquist G, Langer F, Labberton L, Fuchs TA, Bokemeyer C, et al. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood. 2015;126(11):1379\u201389.","journal-title":"Blood"},{"issue":"2","key":"1210_CR49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1160\/TH17-08-0596","volume":"118","author":"E Campello","year":"2018","unstructured":"Campello E, Henderson MW, Noubouossie DF, Simioni P, Key NS. Contact system activation and cancer: new insights in the pathophysiology of cancer-associated thrombosis. Thromb Haemostasis. 2018;118(2):251\u201365.","journal-title":"Thromb Haemostasis"},{"key":"1210_CR50","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12885-016-2359-1","volume":"16","author":"ZA Bazzi","year":"2016","unstructured":"Bazzi ZA, Lanoue D, El-Youssef M, Romagnuolo R, Tubman J, Cavallo-Medved D, et al. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. BMC Cancer. 2016;16:328.","journal-title":"BMC Cancer"},{"issue":"5","key":"1210_CR51","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/MOH.0000000000000068","volume":"21","author":"CM Rein-Smith","year":"2014","unstructured":"Rein-Smith CM, Church FC. Emerging pathophysiological roles for fibrinolysis. Curr Opin Hematol. 2014;21(5):438\u201344.","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"1210_CR52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/jnci\/94.2.116","volume":"94","author":"MP Look","year":"2002","unstructured":"Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94(2):116\u201328.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"1210_CR53","doi-asserted-by":"publisher","first-page":"966","DOI":"10.2174\/138945007781662328","volume":"8","author":"RJ Westrick","year":"2007","unstructured":"Westrick RJ, Eitzman DT. Plasminogen activator inhibitor-1 in vascular thrombosis. Curr Drug Targets. 2007;8(9):966\u20131002.","journal-title":"Curr Drug Targets"},{"issue":"13","key":"1210_CR54","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","volume":"130","author":"Y Hisada","year":"2017","unstructured":"Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499\u2013506.","journal-title":"Blood"},{"issue":"5","key":"1210_CR55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.thromres.2009.11.034","volume":"125","author":"MW Gramling","year":"2010","unstructured":"Gramling MW, Church FC. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res. 2010;125(5):377\u201381.","journal-title":"Thromb Res"},{"key":"1210_CR56","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1111\/jth.15054","volume":"11","author":"RJ Westrick","year":"2020","unstructured":"Westrick RJ, R\u00f8jkjaer LP, Yang AY, Roh MH, Siebert AE, Ginsburg D. Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth. J Thromb Haemost. 2020;11:2968\u201375. https:\/\/doi.org\/10.1111\/jth.15054.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1210_CR57","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1182\/blood.2019000919","volume":"135","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Chan NC. Novel antithrombotic strategies for treatment of venous thromboembolism. Blood. 2020;135(5):351\u20139.","journal-title":"Blood"},{"issue":"3","key":"1210_CR58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.31768\/2312-8852.2016.38(3):187-190","volume":"38","author":"A Ero\u011flu","year":"2016","unstructured":"Ero\u011flu A, Ceylan GG, Ozturk E, Yalcin A, Yalcin B, Karasoy D. The efficacy of tissue factor -603A\/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients. Exp Oncol. 2016;38(3):187\u201390.","journal-title":"Exp Oncol"},{"issue":"3","key":"1210_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/MBC.0000000000000242","volume":"26","author":"MA Wahba","year":"2015","unstructured":"Wahba MA, Ismail MA, Saad AA, Habashy DM, Hafeez ZM, Boshnak NH. Impact of thrombophilic genes mutations on thrombosis risk in Egyptian nonmetastatic cancer patients. Blood Coagul Fibrinolysis. 2015;26(3):309\u201315.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"1210_CR60","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/jth.14759","volume":"18","author":"MY Najem","year":"2020","unstructured":"Najem MY, Couturaud F, Lemari\u00e9 CA. Cytokine and chemokine regulation of venous thromboembolism. J Thromb Haemost. 2020;18(5):1009\u201319.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1210_CR61","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.4110\/in.2018.18.e27","volume":"18","author":"JS Roh","year":"2018","unstructured":"Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Netw. 2018;18(4):e27.","journal-title":"Immune Netw"},{"issue":"46","key":"1210_CR62","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1038\/onc.2016.104","volume":"35","author":"C Hernandez","year":"2016","unstructured":"Hernandez C, Huebener P, Schwabe RF. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene. 2016;35(46):5931\u201341.","journal-title":"Oncogene"},{"key":"1210_CR63","doi-asserted-by":"publisher","unstructured":"Stoiber D, Assinger A. Platelet-leukocyte interplay in cancer development and progression. Cells. 2020;9(4):855.\u00a0https:\/\/doi.org\/10.3390\/cells9040855.","DOI":"10.3390\/cells9040855"},{"key":"1210_CR64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2019.06.919","volume":"288","author":"IC Moschonas","year":"2019","unstructured":"Moschonas IC, Tselepis AD. The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis. Atherosclerosis. 2019;288:9\u201316.","journal-title":"Atherosclerosis"},{"issue":"3","key":"1210_CR65","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/jth.13951","volume":"16","author":"LM Mauracher","year":"2018","unstructured":"Mauracher LM, Posch F, Martinod K, Grilz E, Daullary T, Hell L, et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. J Thromb Haemost. 2018;16(3):508\u201318.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1210_CR66","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/cas.13580","volume":"109","author":"H Krishnan","year":"2018","unstructured":"Krishnan H, Rayes J, Miyashita T, Ishii G, Retzbach EP, Sheehan SA, et al. Podoplanin: An emerging cancer biomarker and therapeutic target. Cancer Sci. 2018;109(5):1292\u20139.","journal-title":"Cancer Sci"},{"issue":"36","key":"1210_CR67","doi-asserted-by":"publisher","first-page":"25993","DOI":"10.1074\/jbc.M702327200","volume":"282","author":"K Suzuki-Inoue","year":"2007","unstructured":"Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282(36):25993\u20136001.","journal-title":"J Biol Chem"},{"issue":"4","key":"1210_CR68","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ajh.2830110405","volume":"11","author":"E Bastida","year":"1981","unstructured":"Bastida E, Ordinas A, Jamieson GA. Differing platelet aggregating effects by two tumor cell lines: absence of role for platelet-derived ADP. Am J Hematol. 1981;11(4):367\u201378.","journal-title":"Am J Hematol"},{"issue":"12","key":"1210_CR69","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/BF01209121","volume":"122","author":"E Heinm\u00f6ller","year":"1996","unstructured":"Heinm\u00f6ller E, Weinel RJ, Heidtmann HH, Salge U, Seitz R, Schmitz I, et al. Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines. J Cancer Res Clin Oncol. 1996;122(12):735\u201344.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1210_CR70","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0952-3278(02)00235-1","volume":"68","author":"X de Leval","year":"2003","unstructured":"de Leval X, Benoit V, Delarge J, Jul\u00e9mont F, Masereel B, Pirotte B, et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (II\/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation. Prostaglandins Leukot Essent Fatty Acids. 2003;68(1):55\u20139.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"1210_CR71","doi-asserted-by":"publisher","unstructured":"Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel).\u00a02018;10:380. https:\/\/doi.org\/10.3390\/cancers10100380.","DOI":"10.3390\/cancers10100380"},{"key":"1210_CR72","doi-asserted-by":"publisher","unstructured":"Reddel CJ, Tan CW, Chen VM. Thrombin generation and cancer: contributors and\u00a0consequences. Cancers. 2019;11(1):100. https:\/\/doi.org\/10.3390\/cancers11010100.","DOI":"10.3390\/cancers11010100"},{"key":"1210_CR73","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3389\/fimmu.2019.01805","volume":"10","author":"AL Palacios-Acedo","year":"2019","unstructured":"Palacios-Acedo AL, Mege D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Platelets, thrombo-inflammation, and cancer: collaborating with the enemy. Front Immunol. 2019;10:1805.","journal-title":"Front Immunol"},{"issue":"16","key":"1210_CR74","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2017-05-743187","volume":"131","author":"XR Xu","year":"2018","unstructured":"Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018;131(16):1777\u201389.","journal-title":"Blood"},{"issue":"5","key":"1210_CR75","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ejim.2013.01.017","volume":"24","author":"HA Goubran","year":"2013","unstructured":"Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med. 2013;24(5):393\u2013400.","journal-title":"Eur J Intern Med"},{"key":"1210_CR76","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12935-017-0460-4","volume":"17","author":"L Repsold","year":"2017","unstructured":"Repsold L, Pool R, Karodia M, Tintinger G, Joubert AM. An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia. Cancer Cell Int. 2017;17:89.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"1210_CR77","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1053\/j.seminoncol.2014.04.010","volume":"41","author":"S Mezouar","year":"2014","unstructured":"Mezouar S, Mege D, Darbousset R, Farge D, Debourdeau P, Dignat-George F, et al. Involvement of platelet-derived microparticles in tumor progression and thrombosis. Semin Oncol. 2014;41(3):346\u201358.","journal-title":"Semin Oncol"},{"issue":"1","key":"1210_CR78","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.beha.2008.12.009","volume":"22","author":"A Falanga","year":"2009","unstructured":"Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22(1):49\u201360.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"1210_CR79","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1055\/s-0039-1693476","volume":"45","author":"R Lacroix","year":"2019","unstructured":"Lacroix R, Vallier L, Bonifay A, Simoncini S, Mege D, Aubert M, et al. Microvesicles and cancer associated thrombosis. Semin Thromb Hemostasis. 2019;45(6):593\u2013603.","journal-title":"Semin Thromb Hemostasis"},{"key":"1210_CR80","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.thromres.2019.09.003","volume":"187","author":"R AmraneDjedidi","year":"2020","unstructured":"AmraneDjedidi R, Rousseau A, Larsen AK, Elalamy I, Van Dreden P, Gerotziafas GT. Extracellular vesicles derived from pancreatic cancer cells BXPC3 or breast cancer cells MCF7 induce a permanent procoagulant shift to endothelial cells. Thromb Res. 2020;187:170\u20139.","journal-title":"Thromb Res"},{"issue":"2","key":"1210_CR81","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12307-012-0123-x","volume":"6","author":"DM Richards","year":"2013","unstructured":"Richards DM, Hettinger J, Feuerer M. Monocytes and macrophages in cancer: development and functions. Cancer Microenviron. 2013;6(2):179\u201391.","journal-title":"Cancer Microenviron"},{"issue":"3","key":"1210_CR82","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1055\/s-0034-1370765","volume":"40","author":"M Demers","year":"2014","unstructured":"Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost. 2014;40(3):277\u201383.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"1210_CR83","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3324\/haematol.2019.217083","volume":"105","author":"Y Hisada","year":"2020","unstructured":"Hisada Y, Grover SP, Maqsood A, Houston R, Ay C, Noubouossie DF, et al. Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors. Haematologica. 2020;105(1):218\u201325.","journal-title":"Haematologica"},{"issue":"32","key":"1210_CR84","doi-asserted-by":"publisher","first-page":"13076","DOI":"10.1073\/pnas.1200419109","volume":"109","author":"M Demers","year":"2012","unstructured":"Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA. 2012;109(32):13076\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1210_CR85","doi-asserted-by":"publisher","first-page":"107602962095428","DOI":"10.1177\/1076029620954282","volume":"26","author":"MS Hamza","year":"2020","unstructured":"Hamza MS, Mousa SA. Cancer-associated thrombosis: risk factors, molecular mechanisms, future management. Clin Appl Thromb Hemost. 2020;26:1076029620954282. https:\/\/doi.org\/10.1177\/1076029620954282.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"1210_CR86","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.thromres.2011.10.025","volume":"129","author":"A Falanga","year":"2012","unstructured":"Falanga A, Marchetti M. Anticancer treatment and thrombosis. Thromb Res. 2012;129(3):353\u20139.","journal-title":"Thromb Res"},{"issue":"2","key":"1210_CR87","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/1358863X14568705","volume":"20","author":"P Oppelt","year":"2015","unstructured":"Oppelt P, Betbadal A, Nayak L. Approach to chemotherapy-associated thrombosis. Vasc Med. 2015;20(2):153\u201361.","journal-title":"Vasc Med"},{"issue":"9","key":"1210_CR88","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.21873\/anticanres.13642","volume":"39","author":"ML Canale","year":"2019","unstructured":"Canale ML, Bisceglia I, Lestuzzi C, Parrini I. Arterial thrombosis in cancer: spotlight on the neglected vessels. Anticancer Res. 2019;39(9):4619\u201325.","journal-title":"Anticancer Res"},{"issue":"Suppl 1","key":"1210_CR89","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.thromres.2018.01.003","volume":"164","author":"D Aronson","year":"2018","unstructured":"Aronson D, Brenner B. Arterial thrombosis and cancer. Thromb Res. 2018;164(Suppl 1):S23\u20138.","journal-title":"Thromb Res"},{"issue":"3","key":"1210_CR90","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/cncr.20347","volume":"101","author":"SR Deitcher","year":"2004","unstructured":"Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004;101(3):439\u201349.","journal-title":"Cancer"},{"issue":"23","key":"1210_CR91","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727\u201341.","journal-title":"JAMA"},{"key":"1210_CR92","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-3-030-20315-3_6","volume":"179","author":"D Jiang","year":"2019","unstructured":"Jiang D, Lee AI. Thrombotic risk from chemotherapy and other cancer therapies. Cancer \u03a4reat Res. 2019;179:87\u2013101.","journal-title":"Cancer \u03a4reat Res"},{"issue":"Suppl 1","key":"1210_CR93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000073282","volume":"33","author":"F Rodeghiero","year":"2003","unstructured":"Rodeghiero F, Elice F. Thalidomide and thrombosis. Pathophysiol Haemost Thromb. 2003;33(Suppl 1):15\u20138.","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"3","key":"1210_CR94","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.critrevonc.2006.07.009","volume":"61","author":"UK Narta","year":"2007","unstructured":"Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007;61(3):208\u201321.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"1210_CR95","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","volume":"152","author":"RF Grace","year":"2011","unstructured":"Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452\u20139.","journal-title":"Br J Haematol"},{"issue":"2","key":"1210_CR96","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/jth.14671","volume":"18","author":"JI Zwicker","year":"2020","unstructured":"Zwicker JI, Wang TF, DeAngelo DJ, Lauw MN, Connors JM, Falanga A, et al. The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. J Thromb Haemost. 2020;18(2):278\u201384.","journal-title":"J Thromb Haemost"},{"key":"1210_CR97","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.phrs.2019.104609","volume":"152","author":"R Roskoski Jr","year":"2020","unstructured":"Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol Res. 2020;152:104609.","journal-title":"Pharmacol Res"},{"issue":"3","key":"1210_CR98","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"1210_CR99","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New Eng J Med. 2001;344(14):1038\u201342.","journal-title":"New Eng J Med"},{"issue":"1","key":"1210_CR100","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/cmdc.200900394","volume":"5","author":"K Skobridis","year":"2010","unstructured":"Skobridis K, Kinigopoulou M, Theodorou V, Giannousi E, Russell A, Chauhan R, et al. Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors. ChemMedChem. 2010;5(1):130\u20139.","journal-title":"ChemMedChem"},{"issue":"1","key":"1210_CR101","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","volume":"16","author":"H Haguet","year":"2017","unstructured":"Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogn\u00e9 JM. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017;16(1):5\u201312.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1210_CR102","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","volume":"41","author":"SP Grover","year":"2021","unstructured":"Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer therapy-associated thrombosis. Arterioscler Thromb Vasc Biol. 2021;41(4):1291\u2013305. This reference is of importance because explains clearly the mechanisms between the cancer therapies and the procoagulant state. Cancer therapies are associated also with a significantly increased risk of thrombosis.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1210_CR103","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","volume":"145","author":"N Alhawiti","year":"2016","unstructured":"Alhawiti N, Burbury KL, Kwa FA, O\u2019Malley CJ, Shuttleworth P, Alzard M, et al. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res. 2016;145:54\u201364.","journal-title":"Thromb Res"},{"issue":"1","key":"1210_CR104","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/ATVBAHA.120.314694","volume":"41","author":"MD Wu","year":"2021","unstructured":"\u2022 Wu MD, Moslehi JJ, Lindner JR. Arterial thrombotic complications of tyrosine kinase inhibitors. Arterioscler Thromb Vasc Biol. 2021;41(1):3\u201310. This reference is of importance because explains that Tyrosine kinase inhibitors (TKIs) that target the breakpoint cluster region-Abelson 1 (BCR-ABL1) have been linked, but not exclusively, to an increased risk of acute arterial thrombotic events, which include acute myocardial infarction and stroke.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"1210_CR105","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393\u2013404.","journal-title":"Blood"},{"issue":"5","key":"1210_CR106","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5):612\u201321.","journal-title":"Lancet Oncol"},{"issue":"20","key":"1210_CR107","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"key":"1210_CR108","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.2147\/DDDT.S211907","volume":"13","author":"D Pantazi","year":"2019","unstructured":"Pantazi D, Ntemou N, Brentas A, Alivertis D, Skobridis K, Tselepis AD. Molecular requirements for the expression of antiplatelet effects by synthetic structural optimized analogues of the anticancer drugs imatinib and nilotinib. Drug Des Devel Ther. 2019;13:4225\u201338.","journal-title":"Drug Des Devel Ther"},{"key":"1210_CR109","doi-asserted-by":"publisher","unstructured":"Kosma A, Pantazi D, Voulgari P, Ntemou N, Brentas A, Alivertis D, et al. Expressing enhanced inhibitory effects toward arachidonic acid induced platelet activation: design, synthesis, DFT calculations and in vitro evaluation of imatinib analogues. ChemistrySelect. 2023;8(11):e202200405.https:\/\/doi.org\/10.1002\/slct.202200405.","DOI":"10.1002\/slct.202200405"},{"issue":"3","key":"1210_CR110","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/ph17030349","volume":"17","author":"L Pechlivani","year":"2024","unstructured":"Pechlivani L, Ntemou N, Pantazi D, Alivertis D, Skobridis K, Tselepis AD. Synthesis of novel nilotinib analogues and biological evaluation of their antiplatelet activity and functionality towards cancer cell proliferation in vitro. Pharmaceuticals. 2024;17(3):349. https:\/\/doi.org\/10.3390\/ph17030349.","journal-title":"Pharmaceuticals"},{"key":"1210_CR111","doi-asserted-by":"publisher","unstructured":"Tullemans BME, Veninga A, Fernandez DI, Aarts MJB, Eble JA, van der Meijden PEJ, et al. Multiparameter evaluation of the platelet-inhibitory effects of tyrosine kinase inhibitors used for cancer treatment. Int J Mol Sci. 2021;22(20):11199. https:\/\/doi.org\/10.3390\/ijms222011199.","DOI":"10.3390\/ijms222011199"},{"issue":"9","key":"1210_CR112","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jth.14225","volume":"16","author":"BME Tullemans","year":"2018","unstructured":"Tullemans BME, Heemskerk JWM, Kuijpers MJE. Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors. J Thromb Haemost. 2018;16(9):1686\u201399.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1210_CR113","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1177\/10781552221098044","volume":"29","author":"V Venkataraman","year":"2023","unstructured":"Venkataraman V, Bales JR, Signorelli J, Hobbs GS. Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitors. J Oncol Pharm Pract. 2023;29(5):1119\u201324.","journal-title":"J Oncol Pharm Pract"},{"issue":"24","key":"1210_CR114","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/bloodadvances.2019000640","volume":"3","author":"G Dobie","year":"2019","unstructured":"Dobie G, Kuriri FA, Omar MMA, Alanazi F, Gazwani AM, Tang CPS, et al. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin \u03b1IIb\u03b23 in mice and humans. Blood Adv. 2019;3(24):4298\u2013311.","journal-title":"Blood Adv"},{"issue":"1","key":"1210_CR115","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.beha.2009.01.001","volume":"22","author":"F Elice","year":"2009","unstructured":"Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol. 2009;22(1):115\u201328.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"1210_CR116","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.semnephrol.2010.09.006","volume":"30","author":"V Eremina","year":"2010","unstructured":"Eremina V, Quaggin SE. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol. 2010;30(6):582\u201390.","journal-title":"Semin Nephrol"},{"issue":"Suppl C","key":"1210_CR117","doi-asserted-by":"publisher","first-page":"C2","DOI":"10.1093\/eurheartj\/suaa004","volume":"22","author":"AJ Mu\u00f1oz Mart\u00edn","year":"2020","unstructured":"Mu\u00f1oz Mart\u00edn AJ, Ram\u00edrez SP, Mor\u00e1n LO, Zamorano MR, Ben\u00e9itez MCV, Salcedo IA, et al. Pharmacological cancer treatment and venous thromboembolism risk. Eur Heart J Suppl. 2020;22(Suppl C):C2-c14.","journal-title":"Eur Heart J Suppl"},{"issue":"Suppl 1","key":"1210_CR118","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.thromres.2022.01.004","volume":"213","author":"F Moik","year":"2022","unstructured":"Moik F, Ay C. Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies. Thromb Res. 2022;213(Suppl 1):S58-s65.","journal-title":"Thromb Res"},{"issue":"10","key":"1210_CR119","doi-asserted-by":"publisher","first-page":"8599","DOI":"10.1007\/s00520-022-06935-5","volume":"30","author":"C Font","year":"2022","unstructured":"Font C, de Herreros MG, Tsoukalas N, Brito-Dellan N, Esp\u00f3sito F, Escalante C, et al. Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies. Support Care Cancer. 2022;30(10):8599\u2013609.","journal-title":"Support Care Cancer"},{"issue":"Suppl 1","key":"1210_CR120","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.thromres.2021.12.017","volume":"213","author":"D Pantazi","year":"2022","unstructured":"Pantazi D, Tselepis AD. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms. Thromb Res. 2022;213(Suppl 1):S95-s102.","journal-title":"Thromb Res"},{"issue":"41","key":"1210_CR121","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"12","key":"1210_CR122","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1007\/s11864-023-01149-1","volume":"24","author":"A Iurlo","year":"2023","unstructured":"Iurlo A, Cattaneo D, Bucelli C, Spallarossa P, Passamonti F. Cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia: clinical relevance, impact on outcome, preventive measures and treatment strategies. Curr Treat Options Oncol. 2023;24(12):1720\u201338.","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"1210_CR123","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(5):452\u201367. This reference is of outstanding importance because constitutes an updated European Society for Medical Oncology (ESMO) Clinical Practice Guideline (CPG) that summarises recommendations for the prevention and treatment of VTE in patients with cancer.","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"1210_CR124","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0049-3848(14)50006-0","volume":"133","author":"AA Khorana","year":"2014","unstructured":"Khorana AA, McCrae KR. Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res. 2014;133(Suppl 2):S35\u20138.","journal-title":"Thromb Res"},{"issue":"1","key":"1210_CR125","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ehjcvp\/pvad075","volume":"10","author":"W Xiong","year":"2024","unstructured":"Xiong W, Agewall S, Yamashita Y. Anticoagulation in cancer-associated thrombosis: how long should the therapy be? Eur Heart J Cardiovasc Pharmacother. 2024;10(1):3\u20134.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"1210_CR126","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/bjh.18276","volume":"198","author":"KM Sanfilippo","year":"2022","unstructured":"Sanfilippo KM, Moik F, Candeloro M, Ay C, Di Nisio M, Lee AYY. Unanswered questions in cancer-associated thrombosis. Br J Haematol. 2022;198(5):812\u201325.","journal-title":"Br J Haematol"},{"key":"1210_CR127","doi-asserted-by":"crossref","unstructured":"Wang TF, Khorana AA, Agnelli G, Bloomfield D, Bonaca MP, B\u00fcller HR, et al. Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. Oncologist. 2023;28(7):555\u201364. This reference is of outstanding importance because describes the effectiveness and safety of factor XI inhibitors for the treatment of VTE associated with cancer.","DOI":"10.1093\/oncolo\/oyad116"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-024-01210-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-024-01210-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-024-01210-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T03:27:25Z","timestamp":1720582045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-024-01210-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":127,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1007\/s11864-024-01210-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"24 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}}]}}